(Q36421154)

English

Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Simpa Salami

2

0 references

object named as

Donna P Ankerst

4

0 references

object named as

Mark A Rubin

6

0 references

author name string

Stephen B Williams

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Meredith M Regan

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

John T Wei

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Ian M Thompson

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Martin G Sanda

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

17 October 2011

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

118

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2651-2658

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Mortality results from a randomized prostate-cancer screening trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Active surveillance for the management of prostate cancer in a contemporary cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Assessing individual risk for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Delayed versus immediate surgical intervention and prostate cancer outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

The role of increasing detection in the rising incidence of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3505607

30 September 2017

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26396

21 January 2018

The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26396

21 January 2018

Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26396

21 January 2018

Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26396

21 January 2018

Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26396

21 January 2018

Prostate cancer early detection. Clinical practice guidelines in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22006057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.26396

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36421154&oldid=1999789753"